학술논문
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
Document Type
Article
Author
Paton, Nicholas I; Kityo, Cissy; Thompson, Jennifer; Nankya, Immaculate; Bagenda, Leonard; Hoppe, Anne; Hakim, James; Kambugu, Andrew; van Oosterhout, Joep J; Kiconco, Mary; Bertagnolio, Silvia; Easterbrook, Philippa J; Mugyenyi, Peter; Walker, A Sarah; Agweng, E; Awio, P; Bakeinyaga, G; Isabirye, C; Kabuga, U; Kasuswa, S; Katuramu, M; Kityo, C; Kiweewa, F; Kyomugisha, H; Lutalo, E; Mugyenyi, P; Mulima, D; Musana, H; Musitwa, G; Musiime, V; Ndigendawan, M; Namata, H; Nkalubo, J; Labejja, P Ocitti; Okello, P; Olal, P; Pimundu, G; Segonga, P; Ssali, F; Tamale, Z; Tumukunde, D; Namala, W; Byaruhanga, R; Kayiwa, J; Tukamushaba, J; Abunyang, S; Eram, D; Denis, O; Lwalanda, R; Mugarura, L; Namusanje, J; Nankya, I; Ndashimye, E; Nabulime, E; Mulima, D; Senfuma, O; Bihabwa, G; Buluma, E; Easterbrook, P; Elbireer, A; Kambugu, A; Kamya, D; Katwere, M; Kiggundu, R; Komujuni, C; Laker, E; Lubwama, E; Mambule, I; Matovu, J; Nakajubi, A; Nakku, J; Nalumenya, R; Namuyimbwa, L; Semitala, F; Wandera, B; Wanyama, J; Mugerwa, H; Lugemwa, A; Ninsiima, E; Ssenkindu, T; Mwebe, S; Atwine, L; William, H; Katemba, C; Abunyang, S; Acaku, M; Ssebutinde, P; Kitizo, H; Kukundakwe, J; Naluguza, M; Ssegawa, K; Namayanja; Nsibuka, F; Tuhirirwe, P; Fortunate, M; Acen, J; Achidri, J; Amone, A; Chamai, M; Ditai, J; Kemigisa, M; Kiconco, M; Matama, C; Mbanza, D; Nambaziira, F; Odoi, M Owor; Rweyora, A; Tumwebaze, G; Kalanzi, H; Katabaazi, J; Kiyingi, A; Mbidde, M; Mugenyi, M; Mwebaze, R; Okong, P; Senoga, I; Abwola, M; Baliruno, D; Bwomezi, J; Kasede, A; Mudoola, M; Namisi, R; Ssennono, F; Tuhirwe, S; Abongomera, G; Amone, G; Abach, J; Aciro, I; Arach, B; Kidega, P; Omongin, J; Ocung, E; Odong, W; Philliam, A; Alima, H; Ahimbisibwe, B; Atuhaire, E; Atukunda, F; Bekusike, G; Bulegyeya, A; Kahatano, D; Kamukama, S; Kyoshabire, J; Nassali, A; Mbonye, A; Naturinda, T M; Ndukukire; Nshabohurira, A; Ntawiha, H; Rogers, A; Tibyasa, M; Kiirya, S; Atwongyeire, D; Nankya, A; Draleku, C; Nakiboneka, D; Odoch, D; Lakidi, L; Ruganda, R; Abiriga, R; Mulindwa, M; Balmoi, F; Kafuma, S; Moriku, E; Hakim, J; Reid, A; Chidziva, E; Musoro, G; Warambwa, C; Tinago, G; Mutsai, S; Phiri, M; Mudzingwa, S; Bafana, T; Masore, V; Moyo, C; Nhema, R; Chitongo, S; Heyderman, Robert; Kabanga, Lucky; Kaunda, Symon; Kudzala, Aubrey; Lifa, Linly; Mallewa, Jane; Moore, Mike; Mtali, Chrissie; Musowa, George; Mwimaniwa, Grace; Sikwese, Rosemary; van Oosterhout, Joep; Ziwoya, Milton; Chimbaka, H; Chitete, B; Kamanga, S; Makwakwa, T Kayinga E; Mbiya, R; Mlenga, M; Mphande, T; Mtika, C; Mushani, G; Ndhlovu, O; Ngonga, M; Nkhana, I; Nyirenda, R; Cheruiyot, P; Kwobah, C; Ekiru, W Lokitala; Mokaya, M; Mudogo, A; Nzioka, A; Siika, A; Tanui, M; Wachira, S; Wools-Kaloustian, K; Alipalli, P; Chikatula, E; Kipaila, J; Kunda, I; Lakhi, S; Malama, J; Mufwambi, W; Mulenga, L; Mwaba, P; Mwamba, E; Mweemba, A; Namfukwe, M; Kerukadho, E; Ngwatu, B; Birungi, J; Paton, N; Boles, J; Burke, A; Castle, L; Ghuman, S; Kendall, L; Hoppe, A; Tebbs, S; Thomason, M; Thompson, J; Walker, S; Whittle, J; Wilkes, H; Young, N; Spyer, M; Kapuya, C; Kyomuhendo, F; Kyakundi, D; Mkandawire, N; Mulambo, S; Senyonjo, S; Angus, B; Arenas-Pinto, A; Palfreeman, A; Post, F; Ishola, D; Arribas, J; Colebunders, R; Floridia, M; Giuliano, M; Mallon, P; Walsh, P; De Rosa, M; Rinaldi, E; Weller, I; Gilks, C; Hakim, J; Kangewende, A; Lakhi, S; Luyirika, E; Miiro, F; Mwamba, P; Mugyenyi, P; Ojoo, S; Paton, N; Phiri, S; van Oosterhout, J; Siika, A; Walker, S; Wapakabulo, A; Peto, T; French, N; Matenga, J; Cloherty, G; van Wyk, J; Norton, M; Lehrman, S; Lamba, P; Malik, K; Rooney, J; Snowden, W; Villacian, J
Source
The Lancet HIV; August 2017, Vol. 4 Issue: 8 pe341-e348, 8p
Subject
Language
ISSN
24054704; 23523018
Abstract
Cross-resistance after first-line antiretroviral therapy (ART) failure is expected to impair activity of nucleoside reverse-transcriptase inhibitors (NRTIs) in second-line therapy for patients with HIV, but evidence for the effect of cross-resistance on virological outcomes is limited. We aimed to assess the association between the activity, predicted by resistance testing, of the NRTIs used in second-line therapy and treatment outcomes for patients infected with HIV.